UCB's Cimzia(R), the Only PEGylated Anti-TNF, Approved in Europe

BRIDGEWATER, N.J., Oct 06, 2009 (BUSINESS WIRE) -- Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced that the
European Commission has approved Cimzia(R), for the treatment of adult
patients with moderately to severely active rheumatoid arthritis (RA).
Cimzia (certolizumab pegol), is a PEGylated anti-TNFa (Tumor Necrosis
Factor alpha). The product is currently being developed by UCB and was
approved in the US in May 2009. Cimzia is one of several products which
utilize Enzon's PEGylation technology, including Oncaspar(R), Adagen(R),
PEGINTRON(R), Macugen(R), and Pegasys(R).

"Our PEGylation technology continues to enable very important
therapeutics like Cimzia, benefiting patients with a wide variety of
diseases," said Jeffrey H. Buchalter, Enzon's president and chief
executive officer.

About Enzon

Enzon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to
developing, manufacturing and commercializing important medicines for
patients with cancer and other life-threatening conditions. The Company
has a portfolio of four marketed products, Oncaspar(R), DepoCyt(R), Abelcet(R)
and Adagen(R). Enzon's drug development programs utilize several
cutting-edge approaches, including its industry-leading PEGylation
technology platform and the Locked Nucleic Acid (LNA) technology.
Enzon's PEGylation technology was used to develop two of its products,
Oncaspar and Adagen, and has created a royalty revenue stream from
licensing partnerships for other products developed using the
technology. Enzon also engages in contract manufacturing for several
pharmaceutical companies to broaden its revenue base. Further
information about Enzon and this press release can be found on the
Company's web site at www.enzon.com.

Forward Looking Statements

There are forward-looking statements contained herein, which can be
identified by the use of forward-looking terminology such as the words
"believes," "expects," "may," "will," "should," "potential,"
"anticipates," "plans" or "intends" and similar expressions. Such
forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause actual results, events or
developments to be materially different from the future results, events
or developments indicated in such forward-looking statements. Such
factors include, but are not limited to the timing, success and cost of
clinical studies; the ability to obtain regulatory approval of products,
market acceptance of, and continuing demand for, Enzon's products and
the impact of competitive products and pricing.A more detailed
discussion of these and other factors that could affect results is
contained in our filings with the U.S. Securities and Exchange
Commission, including our annual report on Form 10-K for the year ended
December 31, 2008. These factors should be considered carefully
and readers are cautioned not to place undue reliance on such
forward-looking statements.No assurance can be given that the
future results covered by the forward-looking statements will be
achieved. All information in this press release is as of the date of
this press release and Enzon does not intend to update this information.